23 research outputs found
Diferencias entre los métodos de determinación de 2.a y 3.a generación de la parathormona sérica sobre la mortalidad en el paciente en hemodiálisis
Parathormone plays a key role in controlling mineral metabolism. PTH is considered a uremic
toxin causing cardiovascular damage and cardiovascular mortality in dialysis patients.
There are two different assays to measure PTH called 2nd generation or intact PTH (iPTH)
and 3rd generation or bioPTH (PTHbio).
Objective: To evaluate the differences in mortality of dialysis patients between both assays
to measure PTH, as well as the possible prognostic role of the PTHbio/iPTH ratio.
Methods: 145 haemodialysis patients were included with 2-year monitoring including baseline
laboratory test and annually thereafter.
Results: 21 patients died in the first year and 28 in the second. No correlation was found
between PTH, PTHbio and PTHbio/iPTH ratio with mortality. Both PTH have a perfect correlation
between them and correlate similarly with other molecules of the mineral metabolism.
The extreme baseline values of PTH are those of higher mortality. In survival by iPTH intervals
(according to guidelines and COSMOS study), a J curve is observed. When iPTH increases,
the ratio decreases, possibly when increasing fragments no. 1–84. There is no greater
prognostic approximation on mortality with PTHbio than PTHi. There was also no difference
in mortality when progression ratio PTHbio/PTHi was analysed.
Conclusions: We didn’t find any advantages to using bioPTH vs. PTHi as a marker of mortality.
BioPTH limits of normality must be reevaluated because its relationship with iPTH is not
consistent. Not knowing these limits affects its prognostic valueLa paratohormona tiene un papel fundamental en el control del metabolismo mineral.
Además es considerada como una toxina urémica al originar dan˜ o cardiovascular e influir
en la mortalidad cardiovascular del paciente en diálisis. Existen dos métodos de medición
denominados de 2.a generación o PTH intacta (PTHi) y de 3.a generación o bioPTH (PTHbio).
Objetivo: Evaluar las diferencias en la mortalidad del paciente en diálisis entre ambas formas
de medición de PTH, así como el posible papel pronóstico de su cociente.
Métodos: Se incluyeron 145 pacientes en hemodiálisis con un seguimiento de 2 an˜ os con
determinación analítica basal y posteriormente de forma anual.
Resultados: Veintiún pacientes fallecieron el primer an˜ o y 28 el segundo. No se encontró
correlación entre PTHi, PTHbio y cociente PTHbio/PTHi con la mortalidad. Ambas PTH tienen
una buena correlación entre ellas y correlacionan de manera similar con otras moléculas del
metabolismo mineral. Los valores basales de PTH extremos son los de mayor mortalidad.
En la supervivencia por tramos de PTHi (según guías y estudio COSMOS) se observa una
curva en J. A mayor aumento de PTHi el cociente desciende, posiblemente al aumentar los
fragmentos no 1-84. No existe una mayor aproximación pronóstica sobre mortalidad con
PTHbio que con PTHi. No se observan diferencias en el valor predictivo del cociente sobre la
mortalidad. Tampoco hubo diferencias en mortalidad cuando se analiza la progresión del
cociente PTHbio/PTHi.
Conclusiones: No encontramos ventajas en la utilización de PTHbio sobre la PTHi como marcador
de mortalidad. Se deben reevaluar los límites de la PTHbio pues su relación con la
PTHi no es constante. El no conocer esos límites condiciona su utilidad pronósticaOur thanks to Maribel Villarino for the help with the development
of the study. L.R.-O. is a Health Professional on Research
Training “Rio Hortega r” (CM13/00131), Ministry of Education,
Government of Spain. R.V.B. is a professional with postdoctoral
contract “Sara Borrell” (CD14/00198) and a project (SAF2014-
60699-JIN) of the Ministry of Economy (MINECO) and FEDER
funds. PI14/00386. PI16/01298. FEDER funds ISCIII-RETIC REDinREN/
RD06/0016, RD12/002
Monocyte chemoattractant protein-1 Is an independent predictor of coronary artery ectasia in patients with acute coronary syndrome
Our purpose was to assess a possible association of inflammatory, lipid and mineral
metabolism biomarkers with coronary artery ectasia (CAE) and to determine a possible association
of this with acute atherotrombotic events (AAT).We studied 270 patients who underwent coronary
angiography during an acute coronary syndrome 6 months before. Plasma levels of several
biomarkers were assessed, and patients were followed during a median of 5.35 (3.88–6.65) years.
Two interventional cardiologists reviewed the coronary angiograms, diagnosing CAE according to
previously published criteria in 23 patients (8.5%). Multivariate binary logistic regression analysis
was used to search for independent predictors of CAE. Multivariate analysis revealed that, aside
from gender and a diagnosis of dyslipidemia, only monocyte chemoattractant protein-1 (MCP-1)
(OR = 2.25, 95%CI = (1.35–3.76) for each increase of 100 pg/mL, p = 0.001) was independent predictor
of CAE, whereas mineral metabolism markers or proprotein convertase subtilisin/kexin type 9
were not. Moreover, CAE was a strong predictor of AAT during follow-up after adjustment for other
clinically relevant variables (HR = 2.67, 95%CI = (1.22–5.82), p = 0.013). This is the first report showing
that MCP-1 is an independent predictor of CAE, suggesting that CAE and coronary artery disease
may share pathogenic mechanisms. Furthermore, CAE was associated with an increased incidence of AATThis work was supported by grants from the following: Fondo de Investigaciones Sanitarias (PI05/0451,
PI05/1497, PI05/52475, PI05/1043, PS09/01405, and PI10/00072, PI14/01567, PI17/01615): http://www.isciii.es/ISCIII/
es/contenidos/fd-investigacion/fd-financiacion/convocatorias-ayudas-accion-estrategica-salud.shtml; Spanish
Society of Cardiology; Spanish Heart Foundation. http://www.secardiologia.es/; Spanish Society of
Arteriosclerosis.www.searteriosclerosis.org; CiberCV. http://www.cibercv.es/; RECAVA (RD06/0014/0035);
www.recava.com; Fundación Lilly. https://www.lilly.es/nuestra-compania/fundacion-lilly-folder; Instituto de
Salud Carlos III FEDER (FJD biobank: RD09/0076/00101); http://www.isciii.es/; and AbbVie Laboratories. http://www.abbvie.es/
Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate
The final publication is avilable at: Journal of Bone and Mineral Metabolism 30.9 (2015): 1-34Chronic kidney disease (CKD)–mineral and bone disorder (MBD) is characterized by increased circulating levels of parathormone (PTH) and fibroblast growth factor 23 (FGF23), bone disease, and vascular calcification, and is associated with adverse outcomes. We studied the prevalence of mineral metabolism disorders, and the potential relationship between decreased estimated glomerular filtration rate (eGFR) and CKD-MBD in coronary artery disease patients in a cross-sectional study of 704 outpatients 7.5 ± 3.0 months after an acute coronary syndrome. The mean eGFR (CKD Epidemiology Collaboration formula) was 75.8 ± 19.1 ml/min/1.73 m2. Our patients showed lower calcidiol plasma levels than a healthy cohort from the same geographical area. In the case of men, this finding was present despite similar creatinine levels in both groups and older age of the healthy subjects. Most patients (75.6 %) had an eGFR below 90 ml/min/1.73 m2 (eGFR categories G2–G5), with 55.3 % of patients exhibiting values of 60–89 ml/min/1.73 m2 (G2). PTH (r = −0.3329, p < 0.0001) and FGF23 (r = −0.3641, p < 0.0001) levels inversely correlated with eGFR, whereas calcidiol levels and serum phosphate levels did not. Overall, PTH levels were above normal in 34.9 % of patients. This proportion increased from 19.4 % in G1 category patients, to 33.7 % in G2 category patients and 56.6 % in G3–G5 category patients (p < 0.001). In multivariate analysis, eGFR and calcidiol levels were the main independent determinants of serum PTH. The mean FGF23 levels were 69.9 (54.6–96.2) relative units (RU)/ml, and 33.2 % of patients had FGF23 levels above 85.5 RU/ml (18.4 % in G1 category patients, 30.0 % in G2 category patients, and 59.2 % in G3–G5 category patients; p < 0.001). In multivariate analysis, eGFR was the main predictor of FGF23 levels. Increased phosphate levels were present in 0.7 % of the whole sample: 0 % in G1 category patients, 0.3 % in G2 category patients, and 2.8 % in G3–G5 category patients (p = 0.011). Almost 90 % of patients had calcidiol insufficiency without significant differences among the different degrees of eGFR. In conclusion, in patients with coronary artery disease there is a large prevalence of increased FGF23 and PTH levels. These findings have an independent relationship with decreased eGFR, and are evident at an eGFR of 60–89 ml/min/1.73 m2. Then, mild decreases in eGFR must be taken in consideration by the clinician because they are associated with progressive abnormalities of mineral metabolismFondo de Investigaciones Sanitarias (PI10/00072, PI14/00386, PIE13/00051, PI05/0451, PI05/1497, PI05/52475, PI05/1043, PS09/01405, PI14/1567) y FRIAT, Spanish Society of Cardiology, Spanish Heart Foundation, Spanish Society of Arteriosclerosis, REDINREN (RD012/0021), Biobank grants from Instituto de Salud Carlos III FEDER, RD09/0076/00101 (FJD Biobank) and Abbvie Laboratories. PN I+D+I 2008-2011 and ISCIII co-financed by FEDER, CIBERDEM and e-PREDIC
Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors
AbstractBackgroundPatients with coronary heart disease (CHD) without classical cardiovascular risk factors (CRFs) are uncommon, and their profile has not been thoroughly studied. In CHD patients, we have assessed the differences in several biomarkers between those with and without CRF.MethodsWe studied 704 patients with CHD, analyzing plasma levels of biomarkers related to inflammation, thrombosis, renal damage, and heart failure: high-sensitivity C-reactive protein (hs-CRP), monocyte chemoattractant protein-1 (MCP-1), galectin-3, N-terminal fragment of brain natriuretic peptide (NT-pro-BNP), calcidiol (vitamin D metabolite), fibroblast growth factor-23 (FGF-23), parathormone, and phosphate.ResultsTwenty patients (2.8%) exhibited no CRFs. Clinical variables were well balanced in both groups, with the logical exceptions of no use of antidiabetic drugs, lower triglyceride and glucose, and higher high-density lipoprotein cholesterol in no-CRF patients.No-CRF patients showed lower hs-CRP (2.574±3.120 vs. 4.554±9.786mg/L; p=0.018), MCP-1 (114.75±36.29 vs. 143.56±65.37pg/ml; p=0.003), and FGF-23 (79.28±40.22 vs. 105.17±156.61RU/ml; p=0.024), and higher calcidiol (23.66±9.12 vs. 19.49±8.18ng/ml; p=0.025) levels. At follow-up, 10.0% vs. 11.0% patients experienced acute ischemic event, heart failure, or death in the non-CRF and CRF groups, respectively (p=0.815, log-rank test). The limited number of non-CRF patients may have influenced this finding. A Cox regression analysis in the whole population showed that high calcidiol, and low MCP-1 and FGF-23 plasma levels are associated with a better prognosis.ConclusionsCHD patients without CRFs show a favorable biomarker profile in terms of inflammation and mineral metabolism. Further studies are needed to investigate whether this difference translates into a better prognosis
Parathormone levels add prognostic ability to N-terminal pro-brain natriuretic peptide in stable coronary patients
Aims: There are controversial data on the ability of the components of mineral metabolism (vitamin D, phosphate, parathormone [PTH], fibroblast growth factor-23 [FGF23], and klotho) to predict cardiovascular events. In addition, it is unknown whether they add any prognostic value to other well-known biomarkers. Methods and results: In 969 stable coronary patients, we determined plasma levels of all the aforementioned components of mineral metabolism with a complete set of clinical and biochemical variables, including N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin I (hs-TnI), and high-sensitivity C-reactive protein. Secondary outcomes were ischaemic events (any acute coronary syndrome, stroke, or transient ischaemic attack) and heart failure or death. The primary outcome was a composite of the secondary outcomes. Median follow-up was 5.39 years. Age was 60 (52–72) years. Median glomerular filtration rate was 80.4 (65.3–93.1) mL/min/1.73 m2. One-hundred and eighty-five patients developed the primary outcome. FGF23, PTH, hs-TnI, and NT-proBNP were directly related with the primary outcome on univariate Cox analysis, while Klotho and calcidiol were inversely related. On multivariate analysis, only PTH (HR 1.058 [CI 1.021–1.097]; P = 0.002) and NT-proBNP (HR 1.020 [CI 1.012–1.028]; P 85.5 RU/mL) (P < 0.001) but not in patients with low FGF23 levels (P = 0.551). There was a significant interaction between FGF23 and PTH (P = 0.002). However, there was no significant interaction between PTH and both klotho and calcidiol levels. Conclusions: Parathormone is an independent predictor of cardiovascular events in coronary patients, adding complimentary prognostic information to NT-proBNP plasma levels. This predictive value is restricted to patients with high FGF23 plasma levels. This should be considered in the design of future studies in this field.This work was supported by grants from Instituto de Salud
Carlos III (ISCIII) and Fondos FEDER (Fondo Europeo de
Desarrollo Regional) European Union (PI05/0451, PI14/1567,
PI17/01615, and PI17/01495); Spanish Society of
Cardiology; Spanish Society of Arteriosclerosis; RECAVA (Red
Temática de Investigación Cooperativa en Enfermedades
Cardiovasculares) (RD06/0014/0035); and Instituto de Salud
Carlos III FEDER (FJD biobank: RD09/0076/00101). The
funders had no role in the study design, data collection and
analysis, decision to publish, or preparation of the
manuscript
¿Debemos adaptarnos los laboratorios clínicos a la realidad del paciente con enfermedad renal crónica en la cuantificación de la hormona paratiroidea?
La aportación del Laboratorio Clínico en el ámbito diagnóstico es cada día mas importante porque gran parte de las decisiones clínicas que se adoptan se basan en nuestros resultados
Should clinical laboratories adapt to the reality of chronic kidney disease in the determination of parathyroid hormone?
The contribution of the clinical laboratory to diagnostics is increasingly important since a great deal of clinical decisions rely on laboratory test results
Differences between 2nd and 3rd generation seric parathormone determination methods on mortality in haemodialysis patients
Parathormone plays a key role in controlling mineral metabolism. PTH is considered a uremic toxin causing cardiovascular damage and cardiovascular mortality in dialysis patients. There are two different assays to measure PTH called 2nd generation or intact PTH (iPTH) and 3rd generation or bioPTH (PTHbio).
Objective: To evaluate the differences in mortality of dialysis patients between both assays to measure PTH, as well as the possible prognostic role of the PTHbio/iPTH ratio.
Methods: 145 haemodialysis patients were included with 2-year monitoring including baseline laboratory test and annually thereafter.
Results: 21 patients died in the first year and 28 in the second. No correlation was found between PTH, PTHbio and PTHbio/iPTH ratio with mortality. Both PTH have a perfect correlation between them and correlate similarly with other molecules of the mineral metabolism. The extreme baseline values of PTH are those of higher mortality. In survival by iPTH intervals (according to guidelines and COSMOS study), a J curve is observed. When iPTH increases, the ratio decreases, possibly when increasing fragments no. 1–84. There is no greater prognostic approximation on mortality with PTHbio than PTHi. There was also no difference in mortality when progression ratio PTHbio/PTHi was analysed.
Conclusions: We didn’t find any advantages to using bioPTH vs. PTHi as a marker of mortality. BioPTH limits of normality must be reevaluated because its relationship with iPTH is not consistent. Not knowing these limits affects its prognostic value
Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease.
BACKGROUND AND OBJECTIVES:We investigated the relationship of the Syntax Score (SS) and coronary artery calcification (CAC), with plasma levels of biomarkers related to cardiovascular damage and mineral metabolism, as there is sparse information in this field. METHODS:We studied 270 patients with coronary disease that had an acute coronary syndrome (ACS) six months before. Calcidiol, fibroblast growth factor-23, parathormone, phosphate and monocyte chemoattractant protein-1 [MCP-1], high-sensitivity C-reactive protein, galectin-3, and N-terminal pro-brain natriuretic peptide [NT-proBNP] levels, among other biomarkers, were determined. CAC was assessed by coronary angiogram as low-grade (0-1) and high-grade (2-3) calcification, measured with a semiquantitative scale ranging from 0 (none) to 3 (severe). For the SS study patients were divided in SS<14 and SS≥14. Multivariate linear and logistic regression analyses were performed. RESULTS:MCP-1 predicted independently the SS (RC = 1.73 [95%CI = 0.08-3.39]; p = 0.040), along with NT-proBNP (RC = 0.17 [95%CI = 0.05-0.28]; p = 0.004), male sex (RC = 4.15 [95%CI = 1.47-6.83]; p = 0.003), age (RC = 0.13 [95%CI = 0.02-0.24]; p = 0.020), hypertension (RC = 3.64, [95%CI = 0.77-6.50]; p = 0.013), hyperlipidemia (RC = 2.78, [95%CI = 0.28-5.29]; p = 0.030), and statins (RC = 6.12 [95%CI = 1.28-10.96]; p = 0.013). Low calcidiol predicted high-grade calcification independently (OR = 0.57 [95% CI = 0.36-0.90]; p = 0.013) along with ST-elevation myocardial infarction (OR = 0.38 [95%CI = 0.19-0.78]; p = 0.006), diabetes (OR = 2.35 [95%CI = 1.11-4.98]; p = 0.028) and age (OR = 1.37 [95%CI = 1.18-1.59]; p<0.001). During follow-up (1.79 [0.94-2.86] years), 27 patients developed ACS, stroke, or transient ischemic attack. A combined score using SS and CAC predicted independently the development of the outcome. CONCLUSIONS:MCP-1 and NT-proBNP are independent predictors of SS, while low calcidiol plasma levels are associated with CAC. More studies are needed to confirm these data
Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease.
OBJECTIVE: Vitamin D and fibroblast growth factor-23 (FGF-23) are related with cardiovascular disorders. We have investigated the relationship of calcidiol (vitamin D metabolite) and FGF-23 plasma levels with the incidence of adverse outcomes in patients with coronary artery disease. METHODS: Prospective follow-up study of 704 outpatients, attending the departments of Cardiology of four hospitals in Spain, 6-12 months after an acute coronary event. Baseline calcidiol, FGF-23, parathormone, and phosphate plasma levels were assessed. The outcome was the development of acute ischemic events (any acute coronary syndrome, stroke, or transient ischemic attack), heart failure, or death. Cox regression adjusted for the main confounders was performed. RESULTS: Calcidiol levels showed a moderate-severe decrease in 57.3% of cases. Parathormone, FGF-23, and phosphate levels were increased in 30.0%, 11.5% and 0.9% of patients, respectively. Only 22.4% of patients had glomerular filtration rate<60 ml/min1.73 m2. After a mean follow-up was 2.15±0.99 years, 77 patients developed the outcome. Calcidiol (hazard ratio [HR] = 0.67; 95% confidence interval [CI] = 0.48-0.94; p = 0.021) and FGF-23 (HR = 1.13; 95% CI = 1.04-1.23; p = 0.005) plasma levels predicted independently the outcome. There was a significant interaction between calcidiol and FGF-23 levels (p = 0.025). When the population was divided according to FGF-23 levels, calcidiol still predicted the outcome independently in patients with FGF-23 levels higher than the median (HR = 0.50; 95% CI = 0.31-0.80; p = 0.003) but not in those with FGF-23 levels below this value (HR = 1.03; 95% CI = 0.62-1.71; p = 0.904). CONCLUSIONS: Abnormalities in mineral metabolism are frequent in patients with stable coronary artery disease. In this population, low calcidiol plasma levels predict an adverse prognosis in the presence of high FGF-23 levels